Cardio Diagnostics Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Cardio Diagnostics Holdings şirketinin toplam hissedar öz sermayesi $3.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $4.5M ve $795.3K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.98m
Eşitlik	US$3.69m
Toplam yükümlülükler	US$795.28k
Toplam varlıklar	US$4.48m

Son finansal sağlık güncellemeleri

We Think Cardio Diagnostics Holdings (NASDAQ:CDIO) Can Afford To Drive Business Growth

Mar 01

Companies Like Cardio Diagnostics Holdings (NASDAQ:CDIO) Are In A Position To Invest In Growth

Nov 02

Recent updates

We Think Cardio Diagnostics Holdings (NASDAQ:CDIO) Can Afford To Drive Business Growth

Mar 01

Companies Like Cardio Diagnostics Holdings (NASDAQ:CDIO) Are In A Position To Invest In Growth

Nov 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CDIO 'nin kısa vadeli varlıkları ( $2.6M ) kısa vadeli yükümlülüklerini ( $308.7K ) aşıyor.

Uzun Vadeli Yükümlülükler: CDIO şirketinin kısa vadeli varlıkları ( $2.6M ) uzun vadeli yükümlülüklerini ( $486.6K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CDIO borçsuzdur.

Borcun Azaltılması: CDIO un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CDIO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CDIO un, serbest nakit akışı her yıl % 51.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Cardio Diagnostics Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Cardio Diagnostics Holdings Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Cardio Diagnostics Holdings Receives an Email Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Cardio Diagnostics Holdings Receives a Written Notice from the Nasdaq Stock Market

We Think Cardio Diagnostics Holdings (NASDAQ:CDIO) Can Afford To Drive Business Growth

Companies Like Cardio Diagnostics Holdings (NASDAQ:CDIO) Are In A Position To Invest In Growth

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 57% to US$2.00

Cardio Diagnostics Holdings, Inc., Annual General Meeting, Nov 15, 2024

Consensus revenue estimates decrease by 89%, EPS upgraded

New major risk - Market cap size

Consensus revenue estimates fall by 16%

Cardio Diagnostics Holdings Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Financial position

Cardio Diagnostics Holdings, Inc. Announces the Availability of its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois

Cardio Diagnostics Holdings, Inc. Announces Publication of Study Showing That Its PrecisionCHD Test Could Save Health Insurers over $113 Million Annually

Price target increased by 33% to US$8.00

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 At the American College of Cardiology’s 73rd Annual Scientific Session

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Cardio Diagnostics Holdings, Inc. Expands Heartrisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

Consensus revenue estimates decrease by 48%, EPS upgraded

Cardio Diagnostics Holdings Unveils Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk

Cardio Diagnostics Holdings, Inc. Appoints Paul F. Burton as Independent Director, Chair of Nominating and Corporate Governance Committee and Member of Audit Committee

Cardio Diagnostics Holdings, Inc. Elects Paul F. Burton as Director

American Medical Association Is Reviewing Cardio Diagnostics Holdings, Inc.'s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes

Consensus revenue estimates increase by 38%

Cardio Diagnostics Holdings Receives an Email Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with Precisionchd Test, Published in the Journal of the American Heart Association

New major risk - Shareholder dilution

Cardio Diagnostics Holdings, Inc., Annual General Meeting, Dec 04, 2023

Cardio Diagnostics Holdings, Inc., Annual General Meeting, Dec 04, 2023

Cardio Diagnostics Holdings Receives a Written Notice from the Nasdaq Stock Market

New major risk - Market cap size

Cardio Diagnostics Holding, Inc’S Actionable Clinical Intelligencetm (Aci) Platform Offers New Epigenetic and Genetic Insights to Inform Coronary Heart Disease Management

We Think Cardio Diagnostics Holdings (NASDAQ:CDIO) Can Afford To Drive Business Growth

High number of new and inexperienced directors

No independent directors

Companies Like Cardio Diagnostics Holdings (NASDAQ:CDIO) Are In A Position To Invest In Growth

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin